Fighting Blindness Research Presentation

694 views

Published on

Presentation by Dr Patrick Corley on Fighting Blindness research for the AGM held in Dublin on October 3, 2009

Published in: Health & Medicine, Business
1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total views
694
On SlideShare
0
From Embeds
0
Number of Embeds
14
Actions
Shares
0
Downloads
11
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Fighting Blindness Research Presentation

  1. 1. Fighting Blindness Annual General Meeting October 2nd 2009
  2. 2. Introduction • Dr Patrick Corley • Assistant Director of Research with Fighting Blindness • Scientist with 11 years laboratory and research training & experience; not a medical doctor • 10 years experience of research grant management. • Disclosure: No financial or other interests related to presentation topic Email: patrick.corley@fightingblindness.ie
  3. 3. Our Vision & Mission • OUR VISION - A world where all sight loss can be prevented or cured. • OUR MISSION - Fighting Blindness will find treatments and cures for sight loss through world-leading research, while providing support to all those affected. - Research - For unmet medical needs
  4. 4. Today's talk • Different to national programme of talks that Fighting Blindness given, Cork, Galway & Dublin • Intend to role these out to other centres in the coming months, Sligo, Waterford, Midlands etc • These are detailed talks, on particular research areas, along with medical updates. • Today talk Brief Overview & View of the future
  5. 5. Research Grants we are funding • 16 research grants at different stages of completion • University College Cork • University College Dublin • University College Galway • Trinity College Dublin • Waterford Institute of Technology • Dublin Institute of Technology • University College London / Moorfield’s Eye Hospital
  6. 6. So this shows we have a lot of activity / work…… Therefore What do we do Now / Next ? Set Goals to Achieve
  7. 7. A Research Strategy
  8. 8. How our Research Strategy Emerged Discussion & Approval Define our Strategic Goals
  9. 9. What are our selected Strategic goals? 1 To lead and drive biomedical research to prevent, treat or cure blindness 2 To increase the amount of funding for dedicated vision research in Ireland 3 To engage and collaborate with leaders in the vision medical and scientific research community 4 To steward, support and advocate for the systematic gathering of relevant patient information for research and planning. 5 To increase the numbers of Irish patients availing of the latest treatments and therapies by advocating for and supporting the development clinical trials infrastructure in Ireland. 6 To raise the National and International Profile of Vision Research
  10. 10. 1) To lead and drive biomedical research to prevent, treat or cure blindness 1 Gene Therapy 2 Stem Cell Technology 3 Retina Implant Technology 4 Novel Drug Therapies 5 Population Studies 6 Clinical trials
  11. 11. 1 Priorities • Gene Therapy • Targets • To carry out gene therapy clinical trials arising from our funded research within 3 years • Stem Cell Technology • Targets • Develop a high profile team of leading stem cell researchers • Develop biological products from stem cells to help repair or stabilise damaged retina • To increase the number of stem cell researchers working on retinal disorders in Ireland.
  12. 12. 2) To increase the amount of funding for dedicated vision research in Ireland • Targets • Maintain the profile of Vision research nationally and internationally • Capitalise and take advantage of funding initiatives aimed at ageing • Create international programmes to up-skill and introduce skills to Ireland • Maintain profile of blindness research distinct from neurodegenerative research
  13. 13. 3) To engage and collaborate with leaders in the vision medical and scientific research arena • Actions • Review, assess and support Networking activities e.g. All Ireland Retina Research Network (AIRRN) and Irish Network of Neural Stem cell Investigators (INNSI). • Enhance linkages with European Vision Institute, EuroVisionNet, Tubingen, Retina International, ARVO etc. • Explore collaborations and professional linkages with sister organisations in the US and Globally
  14. 14. 4) To steward, support and advocate the systematic gathering of relevant patient information for research and planning • Targets • Steward, support and advocate for coordinated patient registries and population studies of blindness in Ireland • Support biobanking and gene banking initiatives • Develop population research into blinding conditions
  15. 15. 5) To increase the numbers of Irish patients availing of the latest treatments and therapies by developing infrastructure for clinical trials in Ireland • Targets: • Support the development of European Vision Institute centres of excellence for Clinical trials at national ophthalmology centres. • Foster Ophthalmic Clinical Research Network • Co-ordinate retinal patient registries in Ireland
  16. 16. 6) To raise the National and International profile of Vision Research Vision Research Institute
  17. 17. Vision Research Institute – Virtual & Actual – Inclusive Model
  18. 18. Key advantages of the Vision Research Institute • To unify our research portfolio across all organizations / institutes and better co-ordinate their activities • To accelerate the gathering and application of patient-relevant scientific knowledge by commissioning dedicated and strategic research. • To employ our own teams of dedicated medical, scientific and paramedical researchers committed to careers in vision research, and to lead global developments in this field. • To claim visible ownership and credit for research achievements, to attract further support for work • To provide a visible hub for Vision Research in Ireland, just as REMEDI has done for stem cell research • To leverage the direct funding invested by Fighting Blindness by winning significant and sustained external research funding.
  19. 19. Lens-ing Effect / Concentrating ss ute dne tit in Ins Bl ch g in ear g ht es Fi n R sio Vi
  20. 20. Thank you !

×